comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Bendamustine - Page 1 : comparemela.com
Current Treatment Options in First-Line MCL
Experts on mantle cell lymphoma discuss first-line treatment options available for patients.
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Treatment-options
Cmcl
Btk-inhibitors
Indolent-biology
Intensive-therapy
Frontline-therapy
Consolidation-therapy
Fasct
Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Peter-martin
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Beyond-setting
Fl
Patient-preference
Cellular-therapy
Clinical-factor
Real-world-data
Quality-of-life
Tazemetostat as Third-line and Beyond Therapy for FL
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Peter-martin
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Beyond-therapy
Third-line-and-beyond
Third-line-treatment
Tazemetostat
Fl
Fl-treatment
Follicular-lymphoma-treatment
CAR T-cells as Third-line and Beyond Therapy for FL
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Bijal-shah
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Beyond-therapy
Fl
Cmcl
Cart-cell-therapy
Bendamustine
Zuma-5
Axicabtagene-ciloleucel
Broad Superiority of Zanubrutinib Over Bendamustine + Rituximab Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without del(17p)
Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).
Constantines-tam
European-research-initiative
Broad-superiority
Zanubrutinib-over-bendamustine
Rituximab-across-multiple-high-risk-factors
Biomarker-subgroup-analysis
Patients-with-treatment-naive-chronic-lymphocytic
Small-lymphocytic-lymphoma-without
Clinical-practice
Sequoia-study
Chronic-lymphocytic-leukemia
vimarsana © 2020. All Rights Reserved.